ÐÂÎÅ×ÊѶ
ÆƾÖÌÇÄò²¡Éö² ¡£¡£¡£¡£¡£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆЧÏÔÖø
ÈÕÆÚ£º
2026Äê06ÔÂ15ÈÕ 15:43
ÌÇÄò²¡Éö²¡ÊÇʲô£¿£¿£¿ £¿£¿£¿£¿£¿
ÌÇÄò²¡Éö² ¡£¡£¡£¡£¡£¨diabetic nephropathy £¬ £¬£¬£¬£¬DN£©ÊÇÌÇÄò²¡×îÑÏÖغÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò» £¬ £¬£¬£¬£¬ÔÚҽѧÉÏÒ²³ÆΪÌÇÄò²¡ÉöСÇòÓ²»¯Ö¢ ¡£¡£¡£¡£¡£ËüÊÇÂýÐÔÉöÔಠ¡£¡£¡£¡£¡£¨chronic kidney disease £¬ £¬£¬£¬£¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಠ¡£¡£¡£¡£¡£¨end stage renal disease, ESRD£©µÄÖ÷Òª²¡Òò1 ¡£¡£¡£¡£¡£ÏÖÔÚ £¬ £¬£¬£¬£¬ÔÚÎÒ¹úÒÔÖÂÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷ÊÆ ¡£¡£¡£¡£¡£
ÌÇÄò²¡Éö²¡ÊÇÓÉÓÚºã¾Ã¸ßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍ¹¦Ð§Öð½¥ÊÜËðµÄ²¡ÀíÀú³Ì ¡£¡£¡£¡£¡£»£»£»£»£»£»£»¼Õß»úÌå±£´æ¼«ÆäÖØ´óµÄ´úлÔÓÂÒ £¬ £¬£¬£¬£¬Ò»µ©Éú³¤µ½ÖÕÄ©½×¶Î £¬ £¬£¬£¬£¬ÍùÍù±ÈÆäËûÉöÔ༲²¡ÖÎÁÆÔ½·¢¼¬ÊÖ ¡£¡£¡£¡£¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌØÕ÷ÐԸıä°üÀ¨ÉöСÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó £¬ £¬£¬£¬£¬Ëæºó·ºÆð΢Á¿°×ÂÑ°×Äò £¬ £¬£¬£¬£¬¼Ì¶øÉú³¤ÎªÁÙ´²ÂÑ°×Äò¡¢ÉöÏËά»¯ £¬ £¬£¬£¬£¬×îÖÕµ¼ÖÂÉö¹¦Ð§¾ÙÐÐÐÔϽµ £¬ £¬£¬£¬£¬Ö±ÖÁÖÕÄ©ÆÚÉöË¥½ß1 ¡£¡£¡£¡£¡£
£¨Í¼Æ¬ÈªÔ´£ºhttps://www.hjtdsm.com/yiyong/dn£©
¼òÎöÏÖÓÐÁÆ·¨ £¬ £¬£¬£¬£¬¿ÉÒÔ·¢Ã÷ £¬ £¬£¬£¬£¬È±·¦Äܹ»Ö±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚÔÚÑ×Ö¢ºÍÏËά»¯Àú³ÌµÄ¶à°ÐµãÒ©Îï £¬ £¬£¬£¬£¬ÊÇÄ¿½ñÌÇÄò²¡Éö²¡ÖÎÁÆÁìÓò×îÖ÷ÒªµÄÁÙ´²Î´Öª×ãÐèÇó ¡£¡£¡£¡£¡£
½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú”£©×ÔÖ÷Ñз¢µÄС·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô¾õÐÍÌÇÄò²¡Éö²¡Ä£×ÓСÊó——db/dbСÊóÉÏÈ¡µÃÁËÏÔÖøÁÆЧ £¬ £¬£¬£¬£¬Í¨¹ý¶à°ÐµãÐͬÔöЧ £¬ £¬£¬£¬£¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡
MCR»·ëÄÁÆЧÏÔÖø
db/dbСÊóÊÇÑо¿ÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£×Ó £¬ £¬£¬£¬£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ £¬ £¬£¬£¬£¬³ýÁ˻᷺Æð·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´ £¬ £¬£¬£¬£¬¸ÃÄ£×ÓСÊóͨ³£»£»£»£»£»£»£»¹ÔÚÉúÃüÔçÆÚÌåÏÖ³öÏÔ×ŵÄÉöСÇòËðÉË£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöСÇòÓ²»¯£© £¬ £¬£¬£¬£¬Ëæ×ÅÄêËêµÄÔöÌí¶ø¼ÓÖØ £¬ £¬£¬£¬£¬»¹ÌåÏÖ³öÖеÈˮƽµÄÂÑ°×Äò ¡£¡£¡£¡£¡£
ÊÔÑéЧ¹ûÏÔʾ £¬ £¬£¬£¬£¬¾ÓÉΪÆÚ8ÖܵÄÖÎÁÆ £¬ £¬£¬£¬£¬Óë¿Õȱ±ÈÕÕ×édb/dbСÊóÏà±È £¬ £¬£¬£¬£¬MCR»·ëĸ߼ÁÁ¿×éСÊóµÄÌÇÉöÏà¹ØÖ¸±ê¾ùÓÐÏÔ×ŵĸÄÉÆ£º
1¡¢ ¶àÌǺÍÌÇÂÑ°×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌÇÂÑ°×ˮƽ£»£»£»£»£»£»£»ÓëÄ£×Ó×éÏà±ÈϽµ·ù¶ÈÔ¼2/3 £¬ £¬£¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»£»£»£»£»£»£»
2¡¢ ½ºÔÂÑ°×ˮƽ£º´ó·ù¶È½µµÍ½ºÔÂÑ°×ˮƽ£¨Ô¼2/3£© £¬ £¬£¬£¬£¬ïÔ̽ºÔ³Á»ý £¬ £¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯Ë®Æ½ £¬ £¬£¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»£»£»£»£»£»£»
3¡¢ ÄòÂÑ°×ˮƽ£ºÖÎÁÆ4Öܽ«ÄòÂÑ°×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë ¡£¡£¡£¡£¡£
ͼ1. db/dbСÊóÉöÔಡ±äͼ
G1¿µ½¡±ÈÕÕ×é/G2Ä£×Ó×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é
MCR»·ëÄ£º¶à°ÐµãÐͬÔöЧ
MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖÐÌåÏÖ³öµÄ׿ԽÁÆЧ £¬ £¬£¬£¬£¬Ô´ÓÚÆä×÷ΪһÖÖÐͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄÆæÒìÉè¼Æ ¡£¡£¡£¡£¡£¸Ã·Ö×ÓʹÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ £¬ £¬£¬£¬£¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î ¡£¡£¡£¡£¡£
ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄÐͬÔöЧЧӦ £¬ £¬£¬£¬£¬ÅäºÏ×÷ÓÃÓÚÌÇÄò²¡Éö²¡µÄ½¹µã²¡Àí»·½Ú £¬ £¬£¬£¬£¬×îÖÕµ¼ÖÂÂÑ°×Äò¼õÇá¡¢×ãϸ°û±£»£»£»£»£»£»£»¤¼°ÉöСÇòÂ˹ý¹¦Ð§¸ÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת £¬ £¬£¬£¬£¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤Õ½ÂÔÔÚÖØ´ó´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ ¡£¡£¡£¡£¡£
¼¤»îMC1R£ºÃâÒßµ÷Àí¿¹Ñ×+ÒÖÖÆÏËά»¯Àú³Ì+Ö±½Ó±£»£»£»£»£»£»£»¤×ãϸ°û
MC1RÖ÷Òª±£´æÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£© ¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R £¬ £¬£¬£¬£¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯ £¬ £¬£¬£¬£¬ïÔÌһϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ±¬·¢2 3£»£»£»£»£»£»£»Í¬Ê±Ôö½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å2 3 £¬ £¬£¬£¬£¬µ÷ÀíÃâÒßϸ°û £¬ £¬£¬£¬£¬¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐÎ £¬ £¬£¬£¬£¬Å¤×ªÉöÔà´ÙÑ×״̬ ¡£¡£¡£¡£¡£
ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦Ð§ËðʧµÄ×îºóͨ· ¡£¡£¡£¡£¡£ÓÐÑо¿Åú×¢ £¬ £¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩ £¬ £¬£¬£¬£¬´Ó¶øïÔ̽ºÔÂÑ°×µÈϸ°ûÍâ»ùÖÊµÄºÏ³É £¬ £¬£¬£¬£¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄÀú³Ì4 ¡£¡£¡£¡£¡£
×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ýÆÁÕϵÄÒªº¦Ï¸°û £¬ £¬£¬£¬£¬ÆäËðÉ˺ÍÍÑÂäÊÇÂÑ°×ÄòµÄÖ÷ÒªÔµ¹ÊÔÓÉ ¡£¡£¡£¡£¡£Ò»Ð©Ñо¿Ö¸³ö £¬ £¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£© £¬ £¬£¬£¬£¬ÎȹÌÆäϸ°û¹Ç¼Ü £¬ £¬£¬£¬£¬ÒÖÖƵòÍö £¬ £¬£¬£¬£¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦Ð§µÄÍêÕûÐÔ £¬ £¬£¬£¬£¬ïÔÌÂÑ°×Äò5 6 ¡£¡£¡£¡£¡£
ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÂþÑÜ5
¼¤»îMC4R£º¸ÄÉÆÒȵºËضԿ¹ºÍ´úл
MC4RÖ÷Òª±£´æÓÚÖÐÊàÉñ¾ÏµÍ³ £¬ £¬£¬£¬£¬¼ÓÈëµ÷ÀíÄÜÁ¿Æ½ºâºÍʳÓû ¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC4R £¬ £¬£¬£¬£¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл £¬ £¬£¬£¬£¬ÓÐÀûÓÚ´ÓȪԴÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡ ¡£¡£¡£¡£¡£
MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ
Õ¹ÍûδÀ´ £¬ £¬£¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆΪ»ùʯ £¬ £¬£¬£¬£¬ÒÀ¸½Æä×÷ÓûúÖƵĽ¹µãÓÅÊÆ £¬ £¬£¬£¬£¬Æð¾¢ÍØÕ¹ÖÐÊàÉñ¾ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦ÖØ´óµÄÐÂ˳Ӧ֢ÁìÓò ¡£¡£¡£¡£¡£
Êг¡Ô¶¾°ÓëÕ½ÂԽṹ
È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔöÌí½×¶Î £¬ £¬£¬£¬£¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õß»áÉú³¤ÎªÌÇÄò²¡Éö²¡ £¬ £¬£¬£¬£¬»¼Õß»ùÊýÖØ´ó ¡£¡£¡£¡£¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª £¬ £¬£¬£¬£¬Ô¤¼Æ2030Ä꽫Áè¼Ý300ÒÚÃÀÔª £¬ £¬£¬£¬£¬Ä긴ºÏÔöÌíÂÊ´ï12.5%7 ¡£¡£¡£¡£¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò £¬ £¬£¬£¬£¬ÕïÁÆÂʵÄÒ»Á¬ÌáÉýʹÆä³ÉΪ×î¾ßÔöÌí»îÁ¦µÄÊг¡Ö®Ò» ¡£¡£¡£¡£¡£
Ö»¹ÜÏÖÓбê×¼ÁÆ·¨Ò»Ö±½ø»¯ £¬ £¬£¬£¬£¬µ«ÉÐÎÞÄܹ»ÄæתÏËά»¯Àú³ÌµÄÌØÒìÐÔÒ©Îï ¡£¡£¡£¡£¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷ÀíÈý´ó½¹µã»·½Úͬʱ½éÈë £¬ £¬£¬£¬£¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÒ컥²¹ £¬ £¬£¬£¬£¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸ÆæÒì²î±ð»¯ÓÅÊÆ ¡£¡£¡£¡£¡£
ÏÖÔÚ £¬ £¬£¬£¬£¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø £¬ £¬£¬£¬£¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Ó붾ÀíѧÑо¿ £¬ £¬£¬£¬£¬Ïà¹Ø½¹µã»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ £¬ £¬£¬£¬£¬¹¹½¨Á˼áʵµÄÊÖÒÕ±ÚÀÝ ¡£¡£¡£¡£¡£ÔÚ´ËרÀû¼Ó³ÖÏ £¬ £¬£¬£¬£¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú½«È«Á¦¼ÓËÙÕâÒ»²î±ð»¯¶àëÄÐÂÒ©µÄÑз¢Àú³Ì £¬ £¬£¬£¬£¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´² £¬ £¬£¬£¬£¬Ô츣ȫÇò»¼Õß £¬ £¬£¬£¬£¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂÔ¸ßµØ ¡£¡£¡£¡£¡£
×ÊÁÏȪԴ
1.Öйú¹«ÖÚ¿µ½¡Íø£¨2014£© £¬ £¬£¬£¬£¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html
2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683
3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815
4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx
5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236
6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf
7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÔ¶¾°ÊÓ²ìÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm
Ïà¹ØÍƼö
2021/03/01
2021/03/01
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ